Recently added

The routine use of a digital tool for the tumor cell fraction quantification in molecular pathology: an international validation of QuANTUM

L'Imperio, Vincenzo; CAPITOLI, GIULIA; Cazzaniga, Giorgio; Mannino, Mauro; Bono, Francesca; Seminati, Davide; Temprana Salvador, Jordi (Pacini Editore, 2025-06)

Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas

Novoa-Testa, Iría; Cordido, Fernando; Rodríguez Berrocal, Víctor; Araujo Castro, Marta; Biagetti, Betina; Menéndez Torre, Edelmiro; Martinez-Saez, Elena (Bioscientifica, 2025-07)

Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)

García Morales, Irene; Soto Insuga, Víctor; SERRANO-CASTRO, PEDRO J; Toledo, Manuel; Serratosa, Jose; Carreno Martinez, Maria del Mar (Elsevier, 2025-08)

Autoantibodies are associated with worse outcomes in MASLD

Soria, Anna; IRUZUBIETA, PAULA; Martin-Mateos, Rosa; Jiménez, Alba; Calixto, Zyanya; Sabiote Cartes, Clara; Díaz, Alba; Salcedo, Maria-Teresa; Pericas, Juan M; muñoz, sergio (Elsevier, 2025-10)

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

He, Jianxing; Tsuboi, Masahiro; Weder, Walter; Chen, Keneng; Hochmair, Maximilian; Shih, Jin-Yuan; MARTINEZ-MARTI, ALEX (American Society of Clinical Oncology, 2025-09-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

HVH - Articles científics: Recent submissions

The routine use of a digital tool for the tumor cell fraction quantification in molecular pathology: an international validation of QuANTUM

Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas

Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)

Autoantibodies are associated with worse outcomes in MASLD

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

HVH - Articles científics: Recent submissions

The routine use of a digital tool for the tumor cell fraction quantification in molecular pathology: an international validation of QuANTUM ﻿

Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas ﻿

Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT) ﻿

Autoantibodies are associated with worse outcomes in MASLD ﻿

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer ﻿

The routine use of a digital tool for the tumor cell fraction quantification in molecular pathology: an international validation of QuANTUM

Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas

Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)

Autoantibodies are associated with worse outcomes in MASLD

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer